Leading, mid-sized CRO continues updating and enhancing technology by Upgrading Safety Database Systems to Oracle Argus 7.0.5
SynteractHCR, a leading, full-service, contract research organization (CRO), continued to enhance its technology support for clients by upgrading its safety database system to the Oracle® Argus 7.0.5 module. This module operates within Oracle’s pharmacovigilance technology platform, Oracle Argus Safety and Interchange. SynteractHCR has become a Gold level member in the Oracle PartnerNetwork program and is also a member of the Oracle Health Sciences CRO Advantage Program as an Argus hosting provider, indicating the staff has been trained to a high level of expertise in Oracle Argus.
Oracle Argus is the premiere, safety, database platform for CROs. This Oracle Argus upgrade improves the aggregate reporting, user functionality, safety data handling, electronic data efficiency, scalability, and customization capabilities that SynteractHCR offers its biopharma clients. The software offers state-of-the-art technology and a cleaner user interface, in addition to strong redundancy and an efficient configurable workflow for SynteractHCR’s clients.
“Our adoption of this software and our relationship with Oracle enables us to provide richer functionalities to our clients, including more automation, customized workflow, effective electronic exchange of data, and more cost effective integration with other data sources. This can increase study efficiencies, allow for more virtually seamless exchanges of information and improve access to study information, all of which helps our clients get to decision points faster,” said Associate Director of Pharmacovigilance Systems Dean Schulenberg, SynteractHCR. “We will continue additional upgrades and enhancements throughout 2016, bringing to our clients what they need to conduct trials safely.”
Through its membership with the Oracle Health Sciences CRO Advantage Program, SynteractHCR is able to expand its offerings to customers. The benefits of membership include more competitive licensing prices, as well as Oracle Argus specialization training.
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.